Boston Scientific/$BSX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Boston Scientific
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Ticker
$BSX
Sector
Primary listing
NYSE
Employees
53,000
Headquarters
Website
BSX Metrics
BasicAdvanced
$154B
55.69
$1.87
0.67
-
Price and volume
Market cap
$154B
Beta
0.67
52-week high
$109.50
52-week low
$85.98
Average daily volume
8.1M
Financial strength
Current ratio
1.508
Quick ratio
0.77
Long term debt to equity
48.929
Total debt to equity
50.973
Interest coverage (TTM)
11.30%
Profitability
EBITDA (TTM)
5,187
Gross margin (TTM)
68.33%
Net profit margin (TTM)
14.43%
Operating margin (TTM)
19.23%
Effective tax rate (TTM)
14.86%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
5.76%
Return on equity (TTM)
12.49%
Valuation
Price to earnings (TTM)
55.685
Price to revenue (TTM)
7.955
Price to book
6.6
Price to tangible book (TTM)
-77.88
Price to free cash flow (TTM)
40.044
Free cash flow yield (TTM)
2.50%
Free cash flow per share (TTM)
2.6
Growth
Revenue change (TTM)
21.61%
Earnings per share change (TTM)
54.68%
3-year revenue growth (CAGR)
15.47%
10-year revenue growth (CAGR)
10.22%
3-year earnings per share growth (CAGR)
64.88%
10-year earnings per share growth (CAGR)
20.23%
What the Analysts think about BSX
Analyst ratings (Buy, Hold, Sell) for Boston Scientific stock.
Bulls say / Bears say
In October 2025, Boston Scientific raised its 2025 adjusted EPS guidance to $3.02–$3.04 after posting Q3 adjusted EPS of $0.75 and revenue of $5.07 billion—both ahead of consensus—driven by cardiovascular device revenue of $3.34 billion (Reuters).
In Q2 2025, the company surpassed profit and revenue forecasts—75 cents adjusted EPS compared to the expected 72 cents, and $5.06 billion in revenue—thanks to strong demand for its Farapulse and Watchman heart rhythm devices. This led to a full-year EPS forecast raise to $2.95–$2.99 (Reuters).
The October 2025 deal to acquire the remaining interest in Nalu Medical for $533 million strengthens Boston Scientific’s chronic pain neuromodulation portfolio with battery-free peripheral nerve stimulation technology; the transaction is expected to be accretive by 2027 (Reuters).
Boston Scientific faces intense competition in the pulsed field ablation market from Johnson & Johnson's Varipulse and Medtronic's PulseSelect, which could limit Farapulse's market share gains and put downward pressure on prices (Reuters).
The company's adjusted operating margins remain vulnerable to an anticipated $100 million tariff impact for 2025, which could reduce profitability further if trade tensions intensify (Reuters).
Although Boston Scientific reported mid-teens revenue growth in China, it warned that the country's bulk procurement program and broader international pricing pressures could squeeze overseas margins and slow future growth (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2025.
BSX Financial Performance
Revenues and expenses
BSX Earnings Performance
Company profitability
BSX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Boston Scientific stock?
Boston Scientific (BSX) has a market cap of $154B as of November 13, 2025.
What is the P/E ratio for Boston Scientific stock?
The price to earnings (P/E) ratio for Boston Scientific (BSX) stock is 55.69 as of November 13, 2025.
Does Boston Scientific stock pay dividends?
No, Boston Scientific (BSX) stock does not pay dividends to its shareholders as of November 13, 2025.
When is the next Boston Scientific dividend payment date?
Boston Scientific (BSX) stock does not pay dividends to its shareholders.
What is the beta indicator for Boston Scientific?
Boston Scientific (BSX) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.